HIV in COVID-19

In this episode, Dr. Pai answers questions specific to HIV in the context of COVID-19, including parallels between the two pandemics, repercussions of COVID-19 on patients with HIV and guidance for handling potential changes to antiretroviral regimens. Questions: From Peter Chin-Hong, MD, at the University of California, San Francisco: "What are the parallels between the HIV and COVID-19 epidemic?" "What lessons can we learn from the early response to HIV that can inform how we approach COVID-19?" "Are HIV patients with COVID-19 doing worse? What information do we have?" "What repercussions of COVID-19 will HIV patients have (mental illness, etc.)?" From Jennifer Ross, PharmD, at the University of Iowa College of Pharmacy: "Many antiretroviral agents (e.g., l lopinavir/ritonavir, boosted darunavir), are being evaluated in clinical trials or are prescribed for off-label use for the treatment or prevention of COVID-19. What additional considerations should be made when proposing a change in a patient's antiretroviral regimen in the midst of COVID-19?" We'd love to hear from you! Send your comments/questions to [email protected]. Be sure to check Healio.com/coronavirus for daily updates on the pandemic and follow us on Twitter @InfectDisNews and @GoHealio. Disclosures: Pai reports serving on the advisory boards of Abbvie and Gilead Sciences.